Adicet Bio, Inc.
200 Constitution Drive
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
For more information, please visit our website at http://www.adicetbio.com.
29 articles with Adicet Bio, Inc.
Dr. Abbot brings extensive industry experience in the research, early product development and clinical translation of cell-based therapies.
Adicet Bio, Inc. announced that it has appointed Elizabeth "E.J." Read, M.D. as its Chief Technology Officer. Dr. Read brings extensive industry experience in the successful development of cell-based biological therapies.
Adicet Bio Announces the Transition of Founder, President and Chief Executive Officer Dr. Aya Jakobovits
Adicet Bio, Inc. ("Adicet"), a biopharmaceutical company focused on the development of next-generation cell immunotherapies, announced today that Aya Jakobovits, Ph.D., Founder of Adicet Bio, has retired from her position as President and Chief Executive Officer.
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
After Bagging $51 Million in Early 2016, Bay Area's Adicet Bio Inks a Five-Year R&D Deal with Regeneron
The Bay Area's Secretive Adicet Bio Raises $51 Million and Buys Israel-based Applied Immune Technologies